About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Hemophilia B Drug ‘Idelvion’ Receives USFDA Approval

by Reshma Anand on March 8, 2016 at 12:21 PM
Font : A-A+

Hemophilia B Drug ‘Idelvion’ Receives USFDA Approval

A biopharmaceutical company's drug has been approved by the US Food and Drug Administration for treating people with hemophilia B.

CSL Behring has developed the drug 'Idelvion' through the recombinant DNA technology. Hemophilia B is a congenital disorder that is characterized by the recurring episodes of bleeding due to deficient recombinant Factor IX.

Advertisement


Idelvion contains a lasting albumin fusion protein that links recombinant coagulation Factor IX with recombinant albumin. The drug has been tested in 90 adult and pediatric patients with the blood disorder. It proved effective for a 7-day and 14-day period by preventing blood loss.

"Idelvion is produced by recombinant DNA technology linking Factor IX to albumin, a protein found in blood, which accounts for the product lasting longer when given intravenously," said the U.S. Food and Drug Administration.
Advertisement

The results showed that 94 percent of bleeds were controlled with one infusion while 99 percent were controlled with one or two infusions. Therefore, patients can inject the drug only once in 15 days or fortnight than injecting it twice or thrice a week. The drug is reported to hit the US markets by this month end while its is already available in Canada.

"Idelvion is the first product from our innovative recombinant factor development program to receive FDA approval. We are proud to add this therapy to our growing portfolio of bleeding disorder products, and are particularly excited abut the positive impact treatment with Idelvion can have on the well-being with patients with hemophilia B," said Andrew Cuthbertson, CSL chief scientific officer.

Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Genetic Counseling Signature Drug Toxicity von Willebrand Disease Bleeding Disorders Hemophilia Budd-Chiari Syndrome 

Most Popular on Medindia

Drug - Food Interactions Loram (2 mg) (Lorazepam) Sanatogen Drug Side Effects Calculator Calculate Ideal Weight for Infants Accident and Trauma Care Diaphragmatic Hernia The Essence of Yoga Sinopril (2mg) (Lacidipine) Hearing Loss Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Hemophilia B Drug ‘Idelvion’ Receives USFDA Approval Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests